全文获取类型
收费全文 | 239189篇 |
免费 | 48642篇 |
国内免费 | 1710篇 |
专业分类
耳鼻咽喉 | 3572篇 |
儿科学 | 7069篇 |
妇产科学 | 4381篇 |
基础医学 | 39146篇 |
口腔科学 | 8187篇 |
临床医学 | 27541篇 |
内科学 | 52507篇 |
皮肤病学 | 11544篇 |
神经病学 | 24687篇 |
特种医学 | 10275篇 |
外国民族医学 | 3篇 |
外科学 | 35125篇 |
综合类 | 3824篇 |
现状与发展 | 7篇 |
一般理论 | 103篇 |
预防医学 | 14213篇 |
眼科学 | 5615篇 |
药学 | 19569篇 |
11篇 | |
中国医学 | 2783篇 |
肿瘤学 | 19379篇 |
出版年
2023年 | 1121篇 |
2022年 | 3067篇 |
2021年 | 6374篇 |
2020年 | 7443篇 |
2019年 | 13823篇 |
2018年 | 13995篇 |
2017年 | 14058篇 |
2016年 | 15542篇 |
2015年 | 16944篇 |
2014年 | 18242篇 |
2013年 | 20166篇 |
2012年 | 16966篇 |
2011年 | 16566篇 |
2010年 | 15908篇 |
2009年 | 11317篇 |
2008年 | 11501篇 |
2007年 | 10309篇 |
2006年 | 9589篇 |
2005年 | 8890篇 |
2004年 | 7952篇 |
2003年 | 7049篇 |
2002年 | 6290篇 |
2001年 | 5250篇 |
2000年 | 4798篇 |
1999年 | 3574篇 |
1998年 | 1363篇 |
1997年 | 1039篇 |
1996年 | 981篇 |
1995年 | 904篇 |
1994年 | 782篇 |
1993年 | 672篇 |
1992年 | 1607篇 |
1991年 | 1593篇 |
1990年 | 1375篇 |
1989年 | 1254篇 |
1988年 | 1167篇 |
1987年 | 1049篇 |
1986年 | 1033篇 |
1985年 | 897篇 |
1984年 | 656篇 |
1983年 | 571篇 |
1982年 | 403篇 |
1981年 | 383篇 |
1980年 | 343篇 |
1979年 | 526篇 |
1978年 | 412篇 |
1977年 | 396篇 |
1976年 | 350篇 |
1974年 | 361篇 |
1973年 | 327篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
Harit Kapoor Kush Raj Lohani Tommy H. Lee Devendra K. Agrawal Sumeet K. Mittal 《CTS Clinical and Translational Science》2015,8(6):841-847
Esophageal adenocarcinoma is the fastest rising cancer in the United States. It develops from long‐standing gastroesophageal reflux disease which affects >20% of the general population. It carries a very poor prognosis with 5‐year survival <20%. The disease is known to sequentially progress from reflux esophagitis to a metaplastic precursor, Barrett''s esophagus and then onto dysplasia and esophageal adenocarcinoma. However, only few patients with reflux develop Barrett''s esophagus and only a minority of these turn malignant. The reason for this heterogeneity in clinical progression is unknown. To improve patient management, molecular changes which facilitate disease progression must be identified. Animal models can provide a comprehensive functional and anatomic platform for such a study. Rats and mice have been the most widely studied but disease homology with humans has been questioned. No animal model naturally simulates the inflammation to adenocarcinoma progression as in humans, with all models requiring surgical bypass or destruction of existing antireflux mechanisms. Valuable properties of individual models could be utilized to holistically evaluate disease progression. In this review paper, we critically examined the current animal models of Barrett''s esophagus, their differences and homologies with human disease and how they have shaped our current understanding of Barrett''s carcinogenesis. 相似文献
35.
Maxime Lafond Shin Yoshizawa Shin‐ichiro Umemura 《Journal of ultrasound in medicine》2019,38(3):567-580
Sonodynamic therapy (SDT) consists of the synergetic interaction between ultrasound and a chemical agent. In SDT, the cytotoxicity is triggered by ultrasonic stimuli, notably through cavitation. The unique features of SDT are relevant in the clinical context more than ever: the need for efficacy, accuracy, and safety while being noninvasive and preserving the patient's quality of life. However, despite the promising results of this technique, only a few clinical reports describe the use of SDT. The objective of this article is to provide an extensive overview of the clinical and preclinical research conducted in vivo on SDT, to identify the limitations, and to detail the developed strategies to overcome them. 相似文献
36.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献
37.
38.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
39.
40.